Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
| Revenue (TTM) | $12.22B |
| Gross Profit (TTM) | $6.65B |
| EBITDA | $4.98B |
| Operating Margin | 38.10% |
| Return on Equity | 24.20% |
| Return on Assets | 12.10% |
| Revenue/Share (TTM) | $47.91 |
| Book Value | $76.18 |
| Price-to-Book | 6.28 |
| Price-to-Sales (TTM) | 10.19 |
| EV/Revenue | 9.52 |
| EV/EBITDA | 23.35 |
| Quarterly Earnings Growth (YoY) | 61.40% |
| Quarterly Revenue Growth (YoY) | 7.80% |
| Shares Outstanding | $253.81M |
| Float | $253.04M |
| % Insiders | 0.21% |
| % Institutions | 100.04% |
Volatility is currently contracting
Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRTX and any ticker you trade — then tracks every position and per-strategy win rate.
